REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range…

View More REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES

Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial

Roche (SIX: RO, ROG; OTCQX: RHHBY) will present the initial results from a Phase Ib study evaluating the efficacy and safety for the combination of…

View More Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial